Innovative Antimetabolites in Solid Tumours:
The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1994
|
| Schriftenreihe: | ESO Monographs, European School of Oncology
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology |
| Beschreibung: | 1 Online-Ressource (VII, 59 p. 1 illus) |
| ISBN: | 9783642792007 |
| DOI: | 10.1007/978-3-642-79200-7 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046144358 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1994 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642792007 |9 978-3-642-79200-7 | ||
| 024 | 7 | |a 10.1007/978-3-642-79200-7 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-79200-7 | ||
| 035 | |a (OCoLC)1119025953 | ||
| 035 | |a (DE-599)BVBBV046144358 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Innovative Antimetabolites in Solid Tumours |c edited by Matti S. Aapro |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 1994 | |
| 300 | |a 1 Online-Ressource (VII, 59 p. 1 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a ESO Monographs, European School of Oncology | |
| 520 | |a The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Toxicology | |
| 650 | 0 | 7 | |a Tumor |0 (DE-588)4078460-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antimetabolit |0 (DE-588)4142687-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Antimetabolit |0 (DE-588)4142687-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Antimetabolit |0 (DE-588)4142687-3 |D s |
| 689 | 1 | 1 | |a Tumor |0 (DE-588)4078460-5 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Aapro, Matti S. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642792021 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540583417 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642792014 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-79200-7 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031524543 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-79200-7 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180479654494208 |
|---|---|
| any_adam_object | |
| author2 | Aapro, Matti S. |
| author2_role | edt |
| author2_variant | m s a ms msa |
| author_facet | Aapro, Matti S. |
| building | Verbundindex |
| bvnumber | BV046144358 |
| classification_rvk | XI 7000 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-79200-7 (OCoLC)1119025953 (DE-599)BVBBV046144358 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-79200-7 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03589nmm a2200577zc 4500</leader><controlfield tag="001">BV046144358</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1994 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642792007</subfield><subfield code="9">978-3-642-79200-7</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-79200-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-79200-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119025953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046144358</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Innovative Antimetabolites in Solid Tumours</subfield><subfield code="c">edited by Matti S. Aapro</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (VII, 59 p. 1 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">ESO Monographs, European School of Oncology</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Tumor</subfield><subfield code="0">(DE-588)4078460-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antimetabolit</subfield><subfield code="0">(DE-588)4142687-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Antimetabolit</subfield><subfield code="0">(DE-588)4142687-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Antimetabolit</subfield><subfield code="0">(DE-588)4142687-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Tumor</subfield><subfield code="0">(DE-588)4078460-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aapro, Matti S.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642792021</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540583417</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642792014</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-79200-7</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031524543</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-79200-7</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046144358 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:25Z |
| institution | BVB |
| isbn | 9783642792007 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031524543 |
| oclc_num | 1119025953 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (VII, 59 p. 1 illus) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1994 |
| publishDateSearch | 1994 |
| publishDateSort | 1994 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| series2 | ESO Monographs, European School of Oncology |
| spelling | Innovative Antimetabolites in Solid Tumours edited by Matti S. Aapro Berlin, Heidelberg Springer Berlin Heidelberg 1994 1 Online-Ressource (VII, 59 p. 1 illus) txt rdacontent c rdamedia cr rdacarrier ESO Monographs, European School of Oncology The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology Oncology Pharmacology/Toxicology Oncology Toxicology Tumor (DE-588)4078460-5 gnd rswk-swf Antimetabolit (DE-588)4142687-3 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Antimetabolit (DE-588)4142687-3 s DE-604 Tumor (DE-588)4078460-5 s Aapro, Matti S. edt Erscheint auch als Druck-Ausgabe 9783642792021 Erscheint auch als Druck-Ausgabe 9783540583417 Erscheint auch als Druck-Ausgabe 9783642792014 https://doi.org/10.1007/978-3-642-79200-7 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Innovative Antimetabolites in Solid Tumours Oncology Pharmacology/Toxicology Oncology Toxicology Tumor (DE-588)4078460-5 gnd Antimetabolit (DE-588)4142687-3 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4078460-5 (DE-588)4142687-3 (DE-588)4073781-0 (DE-588)4143413-4 |
| title | Innovative Antimetabolites in Solid Tumours |
| title_auth | Innovative Antimetabolites in Solid Tumours |
| title_exact_search | Innovative Antimetabolites in Solid Tumours |
| title_full | Innovative Antimetabolites in Solid Tumours edited by Matti S. Aapro |
| title_fullStr | Innovative Antimetabolites in Solid Tumours edited by Matti S. Aapro |
| title_full_unstemmed | Innovative Antimetabolites in Solid Tumours edited by Matti S. Aapro |
| title_short | Innovative Antimetabolites in Solid Tumours |
| title_sort | innovative antimetabolites in solid tumours |
| topic | Oncology Pharmacology/Toxicology Oncology Toxicology Tumor (DE-588)4078460-5 gnd Antimetabolit (DE-588)4142687-3 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Oncology Pharmacology/Toxicology Oncology Toxicology Tumor Antimetabolit Krebs Medizin Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-642-79200-7 |
| work_keys_str_mv | AT aapromattis innovativeantimetabolitesinsolidtumours |